Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › MARITIME-CV

MARITIME-CV

MariTide · Obesity with established CVD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
MariTide
Population
Obesity with established CVD
Official title
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor
Amgen
Phase
Phase 3
Registry status
active not recruiting · 2025-07 → 2028-06
Participants
12800
Registry
NCT07037433

Ongoing outcome trial

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
MARITIME-CVMariTideObesity with established CVD
Obesity + established CVD, with or without T2D
MACE12800recruiting2028-06-30NCT07037433

No results yet; the primary completion date comes from the registry.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: MARITIME-CV. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritime-cv/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.